Global Ophthalmic Drugs Market: Snapshot
The global ophthalmic drugs market is seeing increasing number of co-development agreements among keen players to come up with novel biological agents having lesser treatment durations, players in emerging markets trying to tap into the unmet medical needs, and generic manufacturers strengthening their distribution networks of cost-effective drugs in rural outposts of developing regions, having high proportion of visually challenged people. All this is serving to catalyze growth in the market.
Besides, increasing prevalence of intraocular eye disorders, namely cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, etc., mainly in the elderly, is also stoking growth in the global ophthalmic market. The rising incidence of eye diseases, worldwide, such as dry eye, conjunctivitis, uveitis, and others, is also serving to boost the market. Astute companies in the world are already increasing allocations on investments in research to come up with more effective drugs formulated with novel biological agents.
A report by Transparency Market Research forecasts the global ophthalmic drugs market to rise at a lackluster CAGR of 4.0% between 2017 and 2025 to become worth US$34.3 bn by 2025 from US$24.4 bn in 2016.
Spike in Patients Requiring Long-term Treatment Makes Retinal Disorders Dominant Segment
The global ophthalmic drugs market can be segmented based on disease indication into allergy, dry eye, glaucoma, retinal disorders, infection/inflammation, uveitis, etc. Of them, the retinal disorders segment, which can be further divided into wet age-related macular degeneration, dry age-related macular degeneration, and diabetic retinopathy, among others, leads the market with maximum share. This is mainly on account of the spike in number of patients seeking long-term treatment.
Going forward, however, the dry eye segment is predicted to clock maximum growth on the back of changing environmental conditions, ill-effects of increasing air pollution on eye, lined-up launches of innovative drugs with longer active action, and increased treatment penetration for dry eye.
Keen Players Attempting to Tap into Asia Pacific Market Buoy Growth
From a geographical standpoint, North America leads the global ophthalmic drugs market due to higher uptake of advanced novel products and techniques, and high cost of therapies in all regions. Rising at a CAGR of 4.0% from 2017 to 2025, the market is slated to become worth US$13.08 bn by 2025. Currently, the market in North America is seeing considerable changes on account of changing Medicare policies in the U.S., higher pricing of branded specialty drugs, and the rising patient pool for eye diseases.
Europe trails North America in terms of the size of the market. Numerous big names, actively involved in development of existing ophthalmic drugs to meet the ever-rising demands for the treatment of eye diseases such as cataract, glaucoma, and diabetic retinopathy, are the primary reason for the superior performance of the overall market in the region. Further, approval of new drugs by the European Union for treating eye disorders is also boosting the market in Europe.
Vis-à-vis growth rate, Asia Pacific is predicted to steal the show by registering a CAGR of 4.6% between 2017 and 2025. This is because numerous keen ophthalmology companies are charging into the relatively untapped markets in the region to grow their revenue and market share. China, India, and Malaysia are some of the most attractive markets in the regions on account of a substantial consumer base, rising healthcare spends, and patients’ inclination toward availing improved healthcare facilities.
Some of the key players operating in the global ophthalmic drugs market are ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd.
Global Ophthalmic Drugs Market: Overview
Ophthalmic drugs is a growing market driven by rising prevalence of intraocular eye disorders mainly in elderly population like glaucoma, cataract, age-related macular degeneration, diabetic retinopathy, etc. Also, there is an increasing incidence of eye diseases globally such as dry eye, conjunctivitis, uveitis, and others, and the number of patients suffering from eye diseases is expected to grow exponentially during the forecast period. As a result of this increasing patient pool across the globe, major market players are increasing R&D investments to capture the significant commercial opportunity through innovations in treatment methods, and improvement in drug’s mechanism of action with novel biological agents.
The market overview section of the report comprises qualitative analysis of the overall ophthalmic drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, therapeutic class, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The company share analysis has also been provided for global glaucoma drug market. The pipeline analysis of major as well as emerging market players has been given in the market overview section, along with the product comparison matrix of the major market players. The report also consists of a section depicting the major causes of blindness globally, as well as by regions.
Global Ophthalmic Drugs Market: Segmentation
The global ophthalmic drugs market is segmented in terms of disease indication, therapeutic class, product type, and distribution channels. The disease indication segment is further classified into dry eye, glaucoma, infection/inflammation, retinal disorders, allergy, uveitis, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. Among the disease indication segment, the retinal disorders segment accounted for the largest share of the global ophthalmic drugs market in 2016, owing to factors like exponentially rising patient pool demanding long-term treatment. However, the dry eye segment is expected to grow at a high CAGR during the forecast period, due to changing environmental conditions, pollutions, etc.
In terms of therapeutic class, global ophthalmic drugs market is divided into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF agents, and others. The anti-inflammatory drugs segment is bi-furcated into nonsteroidal anti-inflammatory drugs, and steroids. The anti-infective drugs are further sub-segmented into anti-fungal drugs, anti-bacterial drugs, and others. The anti-glaucoma drugs segment is classified into alpha agonist, beta blockers, prostaglandin analogs, combined medication, and others. On the basis of product type, the market is segmented into prescription drugs and OTC drugs. Based on distribution channels, the global ophthalmic drugs market is segmented into hospital pharmacies, online pharmacies, and independent pharmacies & drug stores.
Geographically, the ophthalmic drugs market has been categorized into five regions namely: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of disease indication, therapeutic class, product type, and distribution channels, along with the CAGR (%) for the forecast period 2017 to 2025.
Global Ophthalmic Drugs Market: Competitive Analysis
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global ophthalmic drugs market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global ophthalmic drugs market such as Aerie Pharmaceuticals, Inc., ALLERGAN, Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Shire among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.
Global Ophthalmic Drugs Market is segmented as follows:
Global Ophthalmic Drugs Market, by Disease Indication
- Dry Eye
- Retinal Disorders
- Wet Age-related Macular Degeneration
- Dry Age-related Macular Degeneration
- Diabetic Retinopathy
Global Ophthalmic Drugs Market, by Therapeutic Class
- Anti-inflammatory Drugs
- Nonsteroidal Anti-inflammatory Drugs
- Anti-infective Drugs
- Anti-fungal Drugs
- Anti-bacterial Drugs
- Anti-glaucoma Drugs
- Alpha Agonist
- Beta Blockers
- Prostaglandin Analogs
- Combined Medication
- Anti-allergy Drugs
- Anti-VEGF Agents
Global Ophthalmic Drugs Market, by Product Type
- Prescription Drugs
- Over-the-Counter Drugs
Global Ophthalmic Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies & Drug Stores
Global Ophthalmic Drugs Market, by Geography
- North America
- Latin America
- Middle East & Africa